Physician profile
Robert E Hunt
NPI 1285652511
$2,157.09
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,941 · 2020: $205 · 2021: $11.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $351.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $242.67 | 2019-2020 | |
| Amgen INC. | $216.65 | 2019-2020 | |
| Celgene Corporation | $200.93 | 2019 | |
| Genentech USA, INC. | $191.14 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $171.81 | 2019 | |
| Pfizer INC. | $145.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $127.34 | 2019 | |
| Ucb, INC. | $122.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $83.79 | 2019 | |
| Horizon Therapeutics Plc | $79.37 | 2019 | |
| Janssen Biotech, INC. | $75.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.04 | 2020 | |
| Radius Health, INC. | $38.19 | 2019 | |
| Tersera Therapeutics LLC | $18.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.13 | 2019 | |
| Assertio Therapeutics, INC. | $16.60 | 2019 | |
| Antares Pharma, INC. | $11.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.